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Objective: Del Nido (DN) cardioplegia solution provides a depolarized hyperkalemic arrest lasting up to 60 minutes,
and the addition of lidocaine may limit intracellular calcium influx. Single-dose DN cardioplegia solution may offer
an alternative myocardial protection strategy to multi-dose cold whole blood (WB) cardioplegia following acute
myocardial infarction (AMI).
Methods: We retrospectively reviewed 88 consecutive patients with AMI undergoing coronary artery bypass (CABG)
surgery with cardioplegic arrest between June 2010 to June 2012. Patients exclusively received WB (n = 40, June
2010-July 2011) or DN (n = 48, August 2011-June 2012) cardioplegia. Preoperative and postoperative data were
retrospectively reviewed and compared using propensity scoring.
Results: No significant difference in age, maximum preoperative serum troponin level, ejection fraction, and STS
score was present between DN and WB. A single cardioplegia dose was given in 41 DN vs. 0 WB patients (p < 0.001),
and retrograde cardioplegia was used 10 DN vs. 31 WB patients (p < 0.001). Mean cardiopulmonary bypass and cross
clamp times were significantly shorter in the DN group versus WB group. Tranfusion rate, length of stay, intra-aortic
balloon pump requirement, post-operative inotropic support, and 30-day mortality was no different between groups.
One patient in the WB group required a mechanical support due to profound cardiogenic shock.
Conclusions: DN cardioplegia may provide equivalent myocardial protection to existing cardioplegia without negative
inotropic effects in the setting of acute myocardial infarction.
Keywords: Coronary artery bypass grafting, Myocardial protection, Acute myocardial infarctionBackground
Despite advances in surgical technique and patient selec-
tion, mortality after coronary artery bypass grafting surgery
(CABG) for acute myocardial infarction (AMI) remains
high at 4-10% [1,2]. Myocardial protection in this setting is
complicated by subsequent ischemia-reperfusion injury,
oxidative stress and intracellular Ca2+ overload [3], all
of which may contribute to post-operative myocardial* Correspondence: ig2006@cumc.columbia.edu
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article, unless otherwise stated.dsyfunction. Current cardioplegia options include whole
blood cardioplegia (WB), Buckberg solution, and warm
blood cardioplegia. However, conflicting evidence exists
regarding the superiority of one solution compared to an-
other. Moreover, solutions designed specifically to address
metabolic changes after AMI or cardiogenic shock, such
as Buckberg solution [4], can be cumbersome to deliver
and are not universally adopted.
Del Nido (DN) cardioplegia was formulated to act as
single-dose administration in pediatric patients. Com-
pared to the traditional 4:1 blood cardioplegia, DN is
more dilute (1:4, blood:crystalloid), has lower Ca+2, andtral Ltd. This is an Open Access article distributed under the terms of the
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Healthcare Inc., Edison, NJ). In pediatric patients, DN
cardioplegia has been shown to result in lower postopera-
tive troponin release compared to WB cardioplegia [5].
However, its use in adults has not been studied, and its
unknown effects on the complex derangements after AMI
have led surgeons to question its use in this sick patient
population. We sought to evaluate the clinical outcomes
of DN cardioplegia in CABG after AMI compared to
standard 4:1 WB solution.
Methods
Patient population
Between July 2010 and July 2012, a total of 828 consecu-
tive patients underwent CABG with or without concomi-
tant cardiac surgical procedures at our institution. Out of
828 patients, 88 consecutive patients with AMI undergoing
isolated CABG surgery with cardioplegic arrest were iden-
tified. AMI was defined as topononin I > 1 ng/mL within
one week prior to operation. Demographic and clinical
outcome data were retrospectively collected from chart re-
view, including age, sex, race, body mass index (BMI), and
comorbid medical conditions, including diabetes, hyper-
tension, chronic obstructive pulmonary disease, renal
failure, smoking history, severe aortic wall calcification,
peripheral arterial disease, cerebrovascular disease, atrial
fibrillation, and prior AMI, percutaneous coronary inter-
vention, or cardiac surgery. The preoperative clinical sta-
tus, including Society of Thoracic Surgeons (STS) risk
score for mortality, New York Heart Association (NYHA)
symptom class, echocardiographic data, and requirement
for intra-aortic balloon pump (IABP) before surgery, was
documented. This study met all guidelines of the Institu-
tional Review Board of Columbia University.
Study design
In the current study, clinical outcomes before and after
adoption of DN were compared using a propensity score
matching analysis. The first group (n = 40) was composed
of a 1-year cohort (July 2010-June 2011) of patients whoTable 1 Composition of Whole Blood (WB) and del Nido
(DN) cardioplegia solutions
4:1 Blood: Cardiogplegia Del Nido
Na (mmol/L) 136-152 143-153
K (mmol/L) 24 24
Cl (mmol/L) 126 132
Mg (mmol/L) 2 6.2
Ca (mmol/L) 0.4
Lidocaine (mg/L) 200 (before XC release) 140
Mannitol (g/L) 12.5 2.6
NaHCO3 50 26underwent isolated CABG following AMI with exclusive
use of WB cardioplegia for myocardial protection (WB
group). The second group (n = 48) was a similar 1-year
cohort (July 2011-July 2012) of patients who underwent
isolated CABG following AMI with exclusive use of DN
cardioplegia for myocardial protection (DN group). A
propensity score matching, based on Greedy 5 to 1 digital
matching algorithm [6], was used to reduce major patient
characteristic differences between groups. Propensity score
matching (1:1) identified 40 matched pairs (in each group)
for analysis.
The primary outcomes included low output syndrome
(LCOS) and in-hospital mortality. The secondary outcomes
were duration of cross-clamp (XC) and cardiopulmonary
bypass (CPB), volume of cardioplegia used, red blood cell
transfusion rate, and in-hospital complications. LCOS was
defined as, if the patient required an IABP or mechanical
circulatory support (MCS) or extra-corporeal membrane
oxygenation (ECMO) in the operating room in order to be
weaned from CPB or in the intensive care unit because of
hemodynamic compromise. LCOS was also diagnosed if
the patient required inotropic medication (at least two of
either vasopressin, dobutamine, milrinone, or epinephrine)
to maintain systolic blood pressure. Patients who required
a renal dose of dopamine (≤3 μg/kg) or a single inotropic
medication support were not considered to have LCOS.Operative details, cardioplegia, and complications
All surgeries were performed using a standard general
anesthesia protocol, median sternotomy approach, employ-
ing cardiopulmonary bypass with mild systemic hypothermia
(30 to 34°C). Intraoperative transesophageal echocardi-
ography was routinely employed. Myocardial protection
was achieved with either WB or DN cardioplegia as fol-
lows. In both groups, the heart was arrested with an in-
duction dose (1 liter) of cold (4°C) cardioplegia using
antegrade and/or retrograde delivery (see Table 1 for
details). In addition, repeated doses of WB cardioplegia
was given via saphenous vein grafts or through the retro-
grade cannula at 20 min intervals in WB patients only. A
second dose (500 ml) of DN was only given if the XC
exceeded 90 minutes.
The operative details that were collected included priority
of surgery (elective, urgent, emergent), cardio-pulmonary
bypass time, global ischemic time, amount and method of
cardioplegia, and number of transfusions. Postoperative
in-hospital complications included need for IABP, ECMO,
or MCS, inotrope dependence on intensive care unit
admission, ventricular or atrial arrhythmia, need for
permanent pace maker, respiratory failure, renal fail-
ure, sepsis or endocarditis, sternal wound infection,
gastrointestinal bleeding, stroke, MI, reoperation for
bleeding, and death before discharge.
Table 2 Baseline demographics
WB DN p
n 40 40
Age (years) 66.6 ± 13.5 68.7 ± 11.7 0.472
Gender (male) (%) 21 (45.7) 25 (54.3) 0.366
BMI (kg/m2) 28.2 ± 5.9 28.1 ± 5.7 0.926
STS risk score (%) 4.6 ± 6.9 3.9 ± 4.2 0.545
Troponin I level (mean) (ng/ml) 15.6 ± 23 14.8 ± 21 0.915
NYHA class (%)
1 5 (12.5) 6 (15) 0.921
2 22 (55) 21 (52.5)
3 12 (30) 11 (27.5)
4 1 (2.5) 2 (5)
Diabetes (%) 18 (45) 22 (55) 0.371
Insulin-dependent (%) 8 (20) 7 (17.5) 0.775
Hypertension (%) 34 (85) 34 (85) 1
Congestive heart failure (%) 5 (12.5) 10 (25) 0.152
LVEF (%) 49.4 ± 12 42.4 ± 12 0.13
Mitral regurgitation > Grade 2 (%) 10 (25) 9 (22.5) 0.925
Tricuspid regurgitation > Grade 2 (%) 3 (7.5) 4 (10) 0.283
Triple-vessel disease (%) 22 (55) 30 (75) 0.061
Quadruple-vessel disease (%) 12 (22.5) 8 (22.5)
Yerebakan et al. Journal of Cardiothoracic Surgery 2014, 9:141 Page 3 of 7
http://www.cardiothoracicsurgery.org/content/9/1/141Propensity score matching and statistical analysis
To permit an independent comparison, logistic regression
and the Greedy 5 to1 Digit Match macro was used to gen-
erate the propensity scores employed for matching [6].
The multivariable logistic regression was run to compute
propensity scores for the two groups (WB and DN) based
on the following covariates: age, gender, STS score, NYHA
class, body mass index (BMI), diabetes, hypertension,
hyperlipidemia, preoperative cardiogenic shock, congestive
heart failure, preoperative left ventricular ejection fraction
(LVEF), number of diseased vessels, renal failure, periph-
eral vascular disease, chronic obstructive pulmonary dis-
ease, and reoperative cardiac surgery. Each patient who
had WB was matched to one patient who had DN cardio-
plegia with the closest propensity score.
Descriptive statistics were used to describe patient char-
acteristics. Categorical data were represented as frequency
distributions and percentages. Continuous variables were
expressed as mean ± standard deviation (SD). Univariate
analysis of continuous variables was performed using stu-
dent t-tests, whereas categorical variables were compared
using chi-square test of homogeneity and independence in
contingency tables. All p-values were two-sided. Data were
analyzed using IBM SPSS Statistics 21.0 (IBM Corp.,
Armonk, NY, USA).Cardiogenic shock (%) 6 (15) 5 (12.5) 0.745
Pre-operative IABP support (%) 5 (12.5) 7 (17.5) 0.531
Previous cardiac surgery (%) 3 (7.5) 1 (2.5) 0.305
Preoperative arrhythmia (%) 10 (25) 6 (15) 0.264
Preoperative Atrial Fibrillation (%) 9 (22.5) 3 (7.5) 0.060
Preoperative stroke (%) 7 (17.5) 6 (15) 0.762
Peripheral vascular disease (%) 8 (20) 8 (20) 1
Preoperative renal failure (%) 4 (10) 6 (15) 0.499
Preoperative Dialysis (%) 1 (2.5) 0 (0) 0.314
COPD (%) 3 (7.5) 5 (12.5) 0.456Results
Baseline demographics
The mean age of the patients was 67.7 ± 12.6 years (range
28–93 years), 57.5% were male, and mean BMI was 28.2 ±
5.7 kg/m2. Mean maximum preoperative serum troponin
level was 15.1 ng/ml (range 1–84.5 ng/ml). Mean STS risk
score for mortality of all patients was 4.3% (range 0.4-
31.1%). The baseline clinical characteristics of the 2
propensity-matched groups (WB vs. DN) were balanced in
all measured characteristics and summarized in Table 2.Cirrhosis (%) 1 (2.5) 1 (2.5) 1
Values are means ± SD, or counts (%). BMI-body mass index, STS-Society of
Thoracic Surgeons, NYHA-New York Heart Association, LVEF-left ventricular
ejection fraction, COPD-chronic obstructive pulmonary disorder.Operative data
Use of DN cardioplegia was associated with significantly
shorter CPB and XC times (both, p < 0.001; Figure 1A).
Additionally, administration of DN cardioplegia resulted
in significant differences in manner and amount of deliv-
ered cardioplegia (all, p < 0.03, Figure 1B). An initial cold
antegrade cardioplegia was used in all patients. A single
cardioplegia dose was given in 33 DN vs. 5 WB patients
(p < 0.001), and retrograde cardioplegia was used in only
8 DN vs. 31 WB patients (p < 0.001). Mean packed red
blood cell (PRBC) transfusion requirements on CPB tended
to be lower with DN versus WB during CBP (1.4 ± 1.5 vs.
0.9 ± 1.3, WB vs. DN, p = 0.113). The operative profiles of
the 2 propensity-matched groups (WB vs. DN) are summa-
rized in Table 3.Postoperative outcomes
Postoperative outcome details are highlighted in Figure 2
and Table 4. In-hospital mortality was statistically compar-
able between groups (p = 0.314). One patient (2.5%) in DN
group died due to profound cardiogenic shock and there
was no hospital mortality in WB group. Additionally, the
prevalence of LCOS was identical in the 2 groups (both
15%, p = 0.99). Newly required postoperative IABP support
was equivalent between groups (WB: 15% vs. DN: 10%,
p = 0.499). Use of postoperative inotropes and dosage
used were similar between groups. Similarly, postoperative
complications such as, unplanned reoperation, readmission
Figure 1 Intraoperative variables. A) Cardiopulmonary bypass and
aortic cross clamp times between groups, B) Total cardioplegia
volume given during operation by treatment group. (Abbreviations:
CPB=cardiopulmonary bypass, DN=del Nido cardioplegia group,
WB=whole blood cardioplegia group, XC=aortic cross-clamp).




Number of grafts 3.2 ± 0.7 3.3 ± 0.6 0.708
Lowest body temperature on CPB (°C) 32.3 ± 1 34.1 ± 2 <0.001
Cardioplegia Delivery (%)
Antegrade 9 (22.5) 32 (80) <0.001
Antegrade + Retrograde 31 (77.5) 8 (20) <0.001
Repeated Dose (Ante or Retro) 35 (87.5) 7 (17.5) <0.001
Cardioplegia Volume
Total initial dose (ml) 1062 ± 198 954 ± 235 0.029
Antegrade-initial (ml) 786 ± 295 944 ± 235 0.010
Retrograde-initial (ml) 266 ± 221 11 ± 47 <0.001
Number of additional doses 3.2 ± 2 0.2 ± 0.4 <0.001
Additional dose amount (ml) 926 ± 591 42 ± 97 <0.001
Reinstitute CPB (%) 1 (2.5) 0 (0) 0.314
PRBC transfusion during CPB 1.4 ± 1.5 0.9 ± 1.3 0.113
Values are means ± SD, or counts (%). CPB-cardioplumonary bypass,
PRBC-packed red blood cells.
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were not significantly different between the 2 groups. Mean
total post-operative PRBC transfusion requirement was sig-
nificantly lower in DN versus WB patients (WB vs. DN,
2.3 ± 2.4 vs.1.3 ± 1.5, p = 0.033). A trend towards lower
duration of ventilation, reduced incidence of postoperative
atrial fibrillation, reduced length of ICU stay, and lower length
of hospital stay was present in DN versus WB patients.
Independent predictors of LCOS in the matched popu-
lation are depicted in Table 5. LVEF < 30% carried the
highest risk of LCOS (OR 7.5, CI: 1.5-37.4) followed by
reoperative cardiac surgery (OR 4.7, CI: 1.2- 45.8) and
then preoperative cardiogenic shock (OR 4.2, CI: 1.6-28.9),
respectively. Importantly, cardioplegia technique was not
found to be an independent predictor of LCOS (OR 0.9,
CI: 0.3-2.7). The multivariable model c statistic was 0.34
and the Hosmer-Lemeshow goodness of fit statistic was
0.63. No multicollinearity was identified.Discussion
Despite advances in anesthesia, surgical techniques, peri-
operative care, and myocardial protection, low cardiac
output syndrome after CABG for AMI confers substan-
tial morbidity and mortality in this population, as high
as 4-7% 30-day mortality in some recent series [2,7]. Nu-
merous myocardial protective solutions have been used
after AMI, most notably warm whole blood and Buckberg
solutions formulated to replenish ATP stores and essential
electrolytes necessary for myocyte contractility [8]. DN so-
lution has not been studied in the AMI setting, and results
of its use in the daily practice of adult cardiac surgery have
yet to be documented. In this manuscript, we present our
experience with Del Nido cardioplegia, a hyperkalemic,
low calcium cardioplegic solution with lidocaine and mag-
nesium additives, in patients undergoing CABG for AMI,
and compare our outcomes to a propensity-matched co-
hort of patients who received our standard WB solution in
the current era. Our primary findings were that: 1) there
was no in-hospital mortality difference in patients receiv-
ing DB vs. WB cardioplegia, 2) intraoperative myocardial
protection, as evidenced by need for inotropes or circula-
tory support, was equivalent in DN and WB patients, 3)
DN use was associated with shorter CPB and XC times.
At our institution, DN has been used for all adult cardiac
surgery since its introduction in 2011.
Two distinct advantages of DN over WB cardioplegia
are apparent from our study data. First, operations utiliz-
ing DN were shorter, despite having similar preoperative
risk factors and undergoing similar numbers of bypass
Figure 2 In-hospital Complications by type of cardioplegia technique. Observed in-hospital post-operative complication rates in patients
underdoing coronary artery bypass grafting after acute myocardial infarction stratified by cardioplegia technique with number of patients (n)
represented next to event rate of each variable for whole blood and Del Nido, respectively. No significant differences were found for any
subgroup except unplanned re-operation. The p values of each variable are presented next to the number of events.
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for cardioplegia administration. With DN, the need for
retrograde and SVG cardioplegia administration is re-
duced (although not eliminated depending on coronary
anatomy), and the hassle of repeated cardioplegia dosing
is eliminated. Repeated dosing can be cumbersome, can
interrupt the flow of the operation, and can be difficult
to time properly. In this setting, a single-dose agent is
highly preferable. Moreover, the reduced ischemic time
(cross-clamp) could prove to have beneficial effects on
clinical outcomes in a larger sample size.
A lower total volume of cardioplegia may reduce hemo-
dilution while on bypass, thus lowering the requirementTable 4 Post-operative outcomes
WB dN p
n 40 40
Postoperative inotropic support 26 (65%) 28 (70%) 0.152
Number of inotropes 1.9 ± 1 2.0 ± 0.9 0.449
Dobutamine dose (μ/kg/min) 4.2 ± 1.1 6.0 ± 1.4 0.124
Norepinephrine dose (μ/min) 4.0 ± 2.6 3.6 ± 2.7 0.592
Vasopressin dose (units/hr) 2.4 ± 1.5 2.7 ± 1.5 0.600
Milrinone dose (μ/kg/min) 0.3 ± 0.1 0.3 ± 0.1 0.057
Ventilation duration (hours) 44.7 ± 87 30.6 ± 47 0.373
Total PRBC Transfusion (mean) (units) 2.3 ± 2.4 1.3 ± 1.5 0.033
ICU stay (days) 7.5 ± 14 4.0 ± 3.0 0.133
Postoperative hospital stay (days) 20.2 ± 24 12.4 ± 9.0 0.048
Values are means ± SD, or counts (%). PRBC-packed red blood cells,
ICU-intensive care unit.for transfusion. The benefits of preventing hemodilution
has been shown with prior cardioplegia solutions - stand-
ard WB or undiluted blood (microplegia) cardioplegia
offer superior myocardial protection when compared
with crystalloid cardioplegia [9]. Moreover, microplegia
has been shown to improve recovery by limiting myo-
cardial edema [10]. Although the optimal dilution of
cardioplegic solutions is still unknown, the added hemo-
concentration afforded with DN administration should
limit edema further than WB or microplegia. In our data,
total blood transfusion requirement was lower with DN
versus WB, likely as result of lower total cardioplegia
volume. Secondary benefits may potentially include
lower duration of ventilator support and reduced hos-




p 95% C.I. for Odds Ratio
Lower Upper
DN cardioplegia 0.879 0.821 0.289 2.675
Female gender 2.056 0.222 0.648 6.526
Preoperative arrhythmia 2.799 0.117 0.773 10.127
Low LVEF, <30% 7.526 0.014 1.515 37.395
Previous Cardiac Surgery 4.735 0.039 1.154 45.809
Shock 4.198 0.029 1.610 28.914
NYHA class, >3 1.187 0.801 0.314 4.492
DN-Del Nido, LVEF-left ventricular ejection fraction, NYHA-New York Heart
Association.
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metabolic changes in myocardial tissue occur due to
deprivation of oxygen and nutrient supply, causing myo-
cardial tissue to behave differently than other conditions.
Consequently mitochondrial damage and energy depletion
impair myocardial contractile function [11]. Anaerobic
glycolysis due to the absence of oxygen results in the
accumulation of lactate and intracellular pH reduction
(to <7.0). The latter activates the Na+-H+ ion exchanger,
thus extruding protons from the cell in exchange for Na+
entry. The impaired function of (Na + K)-ATPase contrib-
utes to exacerbate the intracellular Na+ and Ca2+ overload,
which in turn worsens intolerance to ischemia [3].
Moreover, during hyperkalemic cardioplegic arrest (K+
16–20 mmol/L), membrane potential depolarization
occurs at a membrane potential of −35 to −64 mV, at
which point a small percentage of Na+ and Ca+2 chan-
nels may continue to be active. The net result is con-
tinued intracellular accumulation of Ca+2 during arrest,
which the cell counteracts through energy requiring active
transport mechanisms, and ultimately manifesting as myo-
cardial dysfunction upon reperfusion. It is theorized that
the lidocaine content in DN serves to increase Na+ chan-
nel blockade and minimize the potential for Na+ window
current [5]. This, in addition to its Mg2+ content acting as
Ca2+ antagonist, may represent an important mechanism
of benefit of DN cardioplegia. An effective reduction in
intracellular calcium as a result of this mechanism has
been demonstrated in animal hearts arrested with DN
solution - diastolic intracellular calcium levels were sig-
nificantly lower in DN hearts compared to standard WB
solution, without a negative contractile effect after recov-
ery [12]. Furthermore, a study involving both animals and
pediatric patients [5] comparing WB and DN cardiplegia
also demonstrated superior calcium handling of rat cardi-
omyocytes exposed to DN and reduced troponin T release
after surgery in pediatric patients. Maintenance of primary
calcium handling mechanisms may the most important
biologic mechanism of cytoprotection of DN, but requires
further investigation.
The limitations inherent to a retrospective analysis are
present in this study. Although all patients in our recent
experience were included and matched for preoperative
risk using a propensity analysis, the possibility of selec-
tion bias exists due to differing surgeons, practice refer-
ral patterns for CABG, and the evolving management of
AMI using PCI with modern stent platforms and pharma-
cology. Using recent data and consecutive patients should
minimize this bias, although cannot be excluded short
of a randomized trial. In addition to cohort size being
small, some covariates such as intra- and postoperative
hemodynamic parameters, completeness of revascular-
ization, cardiac biomarker dynamics in postoperative
period, and surgeon’s level of experience could not beincluded in the analysis. Nonetheless, our operative
techniques and postoperative management remained
fairly similar during the time of these 2 cohorts.
Conclusion
Our study showed that myocardial protection with DN
solution in isolated CABG surgery following AMI was
associated with mortality, complications, and preservation
comparable to WB cardioplegia. The reduced CPB and XC
times with DN solution, as well as lower total volume of
cardioplegia, may help shorten lengths of stay and improve
clinical outcomes. In addition, the added benefit of main-
taining continuity of the operation without the need for re-
peated cardioplegia doses cannot be overlooked. Our study
is the first to show clinical outcomes and benefits of dN
cardioplegia in the setting of coronary revascularization for
AMI. Further randomized clinical trial study of the clinical
benefit of DN with single-dose administration, effect on
cytoprotective mechanisms of membrane stabilization, and
dosing regimen in this sick population is warranted.
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